Predictors and impact of non-adherence in adults with attention-deficit/hyperactivity disorder receiving OROS methylphenidate: results from a randomized, placebo-controlled trial

Source: BMC Psychiatry Area: Evidence > Medicines Management > References Background: Medication non-adherence has an important impact on treatment efficacy and healthcare burden across a range of conditions and therapeutic areas.  The aim of this analysis was to determine predictors of non-adherence and impact of non-adherence on treatment response in adults with attention-deficit/hyperactivity disorder (ADHD). Methods: Post-hoc analysis of a 13-week, randomised, double-blind, placebo-controlled study of OROS methylphenidate (MPH) 54 and 72 mg/day at 42 sites in 11 European countries including the UK.  Primary efficacy variable was the Conners' Adult ADHD Rating Scale - Screening Version (CAARS:O-SV).  Daily adherence was calculated as average daily adherence (100 x capsules taken/2), with overall adherence calculated as the average daily adherence.  Predictors of adherence were assessed using mixed-effects logistic regression.  Descriptive statistics were generated for change in CAARS:O-SV score for adherent ...
Source: NeLM - Mental Health - Category: Psychiatry Source Type: news